KIR x ICOS bispecific antibody - Mozart Therapeutics
Alternative Names: KIR x ICOS modulator - Mozart TherapeuticsLatest Information Update: 10 May 2024
At a glance
- Originator Mozart Therapeutics
- Class Anti-inflammatories; Bispecific antibodies; Immunotherapies
- Mechanism of Action CD8 positive T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
Most Recent Events
- 03 May 2024 Preclinical trials in Autoimmune disorders in USA (Parenteral), prior to May 2024
- 03 May 2024 Preclinical trials in Inflammation in USA (Parenteral), prior to May 2024
- 03 May 2024 Pharmacodynamics and adverse events data from a preclinical trial in Inflammation and Autoimmune disorders released by Mozart Therapeutics